Information including the time the pill reached the patient’s stomach and the patient’s activity patterns are transmitted to the patch and then relayed to the patient’s devices such as a mobile phone or other Bluetooth enabled devices. Invega Trinzam is available in the form of extended-release injectable suspension of varying strengths for intramuscular administration. Invega Trinza (paliperidone palmitate) for the Treatment for Schizophrenia, US The sensor, developed by Proteus Digital Health and approved by the FDA in 2012, conveys signals to a wearable, adhesive arm patch after it enters the stomach. The mechanism of action of the drug in treating schizophrenia is unknown and undistinguished.Īblify with Proteus ingestible sensor comprises Abilify embedded with the Proteus ingestible sensor in a single tablet to digitally record ingestion patterns. The drug is available for oral administration in 2mg, 5mg, 10mg, 15mg, 20mg and 30mg dosed tablets. Mechanism of action of sensor embedded AbilifyĪbilify contains an atypical anti-psychotic dopamine partial agonist compound. It is estimated that schizophrenia affects approximately 2.5 million in the US and roughly 1% of the whole population.
Research suggests that schizophrenia may be caused by genetics, environment, brain chemistry and substance usage. People with the disorder are characterised by the inability to think clearly, control over emotions and decisions, depend on others for help, and indulge in hallucinations, delusions, disorganised thinking and abnormal social behaviour. Schizophrenia is a serious mental illness and brain disabling chronic disorder. "Abilify contains an atypical anti-psychotic dopamine partial agonist compound."
0 kommentar(er)
